Fundraising FoxATEM Capital Fund
Venture capitalSeed–Growth · 1 people tracked
Find your way into ATEM Capital Fund
Sign up to find every way you can get introduced to ATEM Capital Fund
- Your email: who you already know at ATEM Capital Fund, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ATEM Capital Fund team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
ATEM Capital invests in life sciences innovation, targeting early-stage breakthrough science led by experienced serial entrepreneurs, fast-growing biopharma companies with diversified pipelines positioned for IPO or M&A within one to three years, and post-revenue companies in AI drug discovery, alternative care, digital therapeutics, and robotics with multi-billion growth potential. The firm favors projects with curative ambition, novel mechanisms of action, innovative delivery platforms, and early signs of efficacy. It emphasizes co-investment with like-minded VCs and selected private deals, leveraging a well-connected advisory board for deal access and insight into emerging Big Pharma needs, with a focus on disciplined decision-making and risk management.
Source: firm website, verified Oct 2, 2026.
Team · 1 people
from public directories
What they invest in
from 6 of 13 portfolio companiesBiotech ×6Healthtech ×3Medical Devices ×2Deep Tech ×1New Materials ×1
HQs:United States×5
Investments · 13 tracked
founders shown can be your intro pathAtea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).
BiotechHealthtechBoston, US
Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in
Co-investorsBain Capital Life SciencesRA Capital
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersLSP (Life Sciences Partners)Octalfa+5 more
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorAlamo Angels+9 more
BiotechGermantown, US
John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)
Co-investorsLumira VenturesPlains VenturesEcho Investment CapitalLeaps by BayerMPM BioImpact
Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids.
BiotechDeep TechNew Materials
Co-investorsConnecticut InnovationsDuke Capital PartnersLifeSci Venture PartnersLongley CapitalWestern Digital CapitalPrime Movers Lab
Late-stage oncology company using epigenetics to overcome resistance in cancer treatment.
Co-investorsAisling CapitalAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 CapitalPappas Capital
Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment.
BiotechHealthtechMedical DevicesAustin, US
TERESA MCROBERTS(Executive Officer)inPAUL LAMMERS, MD, MSc(Executive Officer, Director)inJON IRVIN(Executive Officer)in
BoardDANIEL JANSE(Director)JURGEN ECKHARDT(Director)ELIZABETH WILLIAMS(Director)
Co-investorsB Capital GroupB4 CapitalCheckmate Capital Group LLCLeaps by BayerNorthpond VenturesOceanpine Capital
.jpeg){kind=logo}
Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease.
BiotechMedical Devices
Co-investorsARCH Venture PartnersPandect BioventuresUCB Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ArpeggioAteaTobira Therapeutics
Exits · 1
1 IPOsAtea PharmaceuticalsNASDAQ: AVIR
Frequently asked questions
- How many investments has ATEM Capital Fund made?
- ATEM Capital Fund has 13 tracked investments, 1 of which have exited.
- What stage does ATEM Capital Fund invest at?
- ATEM Capital Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does ATEM Capital Fund focus on?
- ATEM Capital Fund focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices, Robotics.